ARHGAP27P2: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Target Name: ARHGAP27P2

NCBI ID: G440461

ARHGAP27P2

Other Name(s): Rho GTPase activating protein 27 pseudogene 2

ARHGAP27P2: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Guanosine triphosphate (GTP) is a crucial molecule in various cellular processes, including intracellular signaling, mRNA translation, and vesicle transport. GTPase-activating proteins (GAPs) are a family of transmembrane proteins that regulate GTPase activity by interacting with GTP-binding sites. Rho GTPase activating protein 27 (ARHGAP27P2) is a GAP that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

ARHGAP27P2: Structure and Function

ARHGAP27P2 is a 21 kDa protein that contains a catalytic active site, a nucleotide-binding oligomerization domain (NBO), and a C-terminal hypervariable region (HVR). The NBO is responsible for interacting with GTP-binding sites, while the HVR is involved in protein-protein interactions and modulation of protein stability.

ARHGAP27P2 has been shown to play a critical role in various cellular processes, including the regulation of cell proliferation, differentiation, and survival. For example, ARHGAP27P2 has been shown to promote the growth and survival of cancer cells, and it has been proposed as a potential cancer therapeutic. Additionally, ARHGAP27P2 has been linked to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Drug Targeting and Biomarker

The ARHGAP27P2 protein has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. Several studies have suggested that inhibition of ARHGAP27P2 could be a effective strategy for treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the potential drug targets for ARHGAP27P2 is its role in cell proliferation. Several studies have shown that ARHGAP27P2 promotes the growth and survival of cancer cells, and that inhibition of its activity could be an effective strategy for cancer treatment. For example, a small molecule inhibitor, NB-5024, has been shown to inhibit the activity of ARHGAP27P2 and prevent the growth and survival of cancer cells.

Another potential drug target for ARHGAP27P2 is its role in neurodegenerative diseases. Several studies have shown that ARHGAP27P2 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, inhibition of its activity could be an effective strategy for treating neurodegenerative diseases.

In addition to its potential drug targets, ARHGAP27P2 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The expression of ARHGAP27P2 has been shown to be increased in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, its levels could be used as a diagnostic or predictive marker for these diseases.

Conclusion

ARHGAP27P2 is a GAP that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and the involvement in various cellular processes make it an attractive target for drug development. Further studies are needed to fully understand the role of ARHGAP27P2 in disease progression and to develop effective strategies for its inhibition.

Protein Name: Rho GTPase Activating Protein 27 Pseudogene 2

The "ARHGAP27P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP27P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets